Please login to the form below
lenvatinib
This page shows the latest lenvatinib news and features for those working in and with pharma, biotech and healthcare.
Merck says it has plenty in the pipe beyond Keytruda
AstraZeneca-partnered Lynparza (olaparib) and Eisai-partnered Lenvima (lenvatinib) that the company is also expecting to show significant growth in the coming years.
Latest news
-
Analysts look beyond Keytruda in Merck’s future
Human papillomavirus (HPV) vaccine Gardasil was up a third to $835m, and there were good performances for cancer drugs Lynparza (olaparib) and Lenvima (lenvatinib), partnered with AstraZeneca and Eisai, respectively.
-
Pfizer’s plans for Inlyta go awry with failed adjuvant trial
nivolumab) and Exelixis’ multikinase inhibitor Cabometyx (cabozantinib) - backed by strong overall survival data - as well as Eisai’s multikinase drug Lenvima (lenvatinib).
-
$5.76bn deal puts Merck closer to Eisai and fast-growing Lenvima
rights for Lenvima (lenvatinib) and start a series of clinical trials in combination with Keytruda (pembrolizumab).
-
NICE reverses its rejection of Eisai’s Lenvima
The cost-effectiveness watchdog has now backed the thyroid cancer treatment. The National Institute for Health and Care Excellence (NICE) has recommended the use of Lenvima (lenvatinib) after manufacturer Eisai was ... that NICE is finally recommending
-
NICE gives green light to Ipsen's Cabometyx
Meanwhile, NICE is in the process of assessing Eisai’s Kisplyx (lenvatinib) - approved by European regulators in 2016 as a second-line combination treatment for advanced RCC, guidance from England’s
More from news
Approximately 2 fully matching, plus 16 partially matching documents found.
Latest Intelligence
-
Eisai: Bucking the trend with R&D growth
The monoclonal antibody farletuzumab is in phase III trials for ovarian cancer, and has reached the phase II stage for non-small cell lung cancer, while lenvatinib is also in phase
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
Featured jobs
- Account Director, Healthcare Communications
-
Salary TBC
- FREELANCE Account Director – Healthcare Advertising – London – 3...
-
Competitive Daily Rates
- Senior Account Executive – Account Manager – Healthcare Advertis...
-
£32000 - £43000 Bonus Benfits
-
Account Director – UK Office
-
Excellent salary and benefits
- Senior Medical Writer, Healthcare Advertising Agency
-
£45, 000 – £50, 000
Subscribe to our email news alerts
- AZ, Merck’s Lynparza scores market-expanding clinical success
- Moving annual total (MAT)
- GSK hires Merck KGaA exec to lead US pharma business
- Roche undercuts price of Bayer cancer drug after winning FDA approval
- Leaked no-deal Brexit document forecasts widespread shortages
- Novartis chooses internal replacement for US pharma president role
PMHub
Healthcare Media Europe – HME Ltd
HME are an innovative and technology enabled agency offering our clients over 35+ years of knowledge and expertise in delivering...
Latest intelligence
- Empowered patients: shaking the foundations of healthcare
- Precision medicine represents a new paradigm in healthcare.This new approach to treating and preventing disease views the patient holistically, analysing their genes, environment and lifestyle, and using this information to...
- A uniquely English genomic medicine service
- The UK National Health Service is developing one standardised approach to embedding precision medicine across the whole of England. Blue Latitude Health speaks to Dr Tom Fowler, Deputy Chief Scientist...
- Blended Intelligence
- Data is the most valued commodity of the modern world. For P&P it's all about the application....
Quick links
Infographics
